Predictive Value of Copeptin in the Diagnosis of Acute Ischemic Stroke

In the USA, every year 795,000 patients suffer a cerebral vascular accident (CVA), which represents a yearly cost of $73.7 billion. CVA is the third main cause of death and the main source of acquired handicap in adults, as a result it is now a key priority in public health and part of " The CVA National Action Plan 2013-2014".

Copeptin is a polypeptide, by- product of Vasopressin metabolism. The increase of Copeptin plasma level, as for Vasopressin, is connected to hydric balance disorders found in cardio-vascular, renal and endocrine diseases. This link has already shown its interest in the early diagnosis of myocardial infarction and, in a more indirect way, CVA.

Copeptin is associated with acute endogenous stress. It seems to have interesting potential in the diagnosis of CVA by its negative predictive value like D-dimeres in pulmonary embolism. Proadrenomedullin and Brain Natriuretic Peptide (BNP) are both associated with the prognosis of cardio-vascular diseases and could be interesting in evaluating CVA prognosis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cerebral Vascular Accident (CVA) Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Nervous System Diseases Stroke Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Service des Urgences Médico-Chirugicales Adultes Hôpitaux Universitaires

Strasbourg, 67098, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All patients, male or female, may be included if they meet the following criteria:
patients with suspected ischemic CVA admitted in an acute stroke unit (thrombolysis unit).
aged 18 and over.
MRI Scan undertaken under the current protocol which includes the following sequences: distribution, T2* (gradient echo), ARM, TOF and FLAIR.
after information given the consent form is signed:

by the patient .or for those unable to express their consent (in case of coma or severe neurological disorder) by a relative or next of kin.

.the patient will be informed as soon as he has recovered his faculties in order to be able to express, if he wishes, his opposition to the pursuit of the research (sample destruction before tested).

the patient must be registered with the Social Security

Exclusion criteria

All patients with a contraindication to MRI Scan:

Pacemaker,
Implanted cardiac defibrillator,
Implanted Neuro-stimulator,
Cochlear Implants
Implanted Insulin pump
Other implanted electronic medical device
Vascular intracerebral Clip
Cardiac Valve
Other metallic implant
Metallic foreign body
Ventricular diversion valve
Eye or hearing prosthesis
Current or suspected pregnancy
Breast feeding

Those who are under protection of justice, under guardianship or curatorship will also be excluded.

Treatment and study plan

(for each intervention)

Biological

Blood Test

Other

Primary outcomes

Determine the minimum level of Copeptin required to determine if the patients present with acute CVA or not.

Time frame: Participants will be followed during 90 days

Copeptin is associated with acute endogenous stress. It seems to have interesting potential in the diagnosis of CVA by its negative predictive value like D-dimers in pulmonary embolism. Proadrenomedullin and Brain Natriuretic Peptide (BNP) are both associated with the prognosis of cardio-vascular diseases and could be interesting in evaluating CVA prognosis

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Important dates

Study start: 2014
Primary completion: 2014
Study completion: 2014
First posted: Oct 10, 2013
Registry last updated: Mar 9, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed